Breast Cancer: Update Bulletin # 3 [February 2019]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the European Commission’s (EC) approval for an expanded indication of Novartis’ Kisqali (ribociclib), a CDK4/6 inhibitor for HER2-negative/HR-positive BC;Roche announcing data from the Phase III KATHERINE trial, showing that Kadcyla (trastuzumab emtansine) was significantly better than Herceptin (trastuzumab; Roche) at reducing the risk of BC recurrence in certain patients with residual disease after surgery; as well as Puma Biotechnology announcing top-line Phase III NALA data of Nerlynx (neratinib) plus capecitabine versus Tykerb/Tyverb (lapatinib; Novartis) plus capecitabine as a third-line therapy in HER2-positive metastatic BC.

Business Questions:

• Will the expanded approval of Kisqali result in increased prescribing?
• According to KOLs, how is Kisqali faring against the first-to-market Ibrance?
• What are KOL reactions to the Phase III KATHERINE study of Kadcyla?
• According to KOLs, will Kadcyla be approved in the adjuvant setting?
• What do KOLs think of the Nerlynx Phase III NALA data?
• If approved, could Nerlynx threaten lapatinib in the third-line metastatic setting?